Dr. Thomas Reed was a founder of Genomatix, which became the publicly traded company Intrexon, and is now known as Precigen. Dr. Reed served as Chief Science Officer of Intrexon for over 20 years and launched BioSolution Designs in April 2020. www.tdrDNA.com
Sam Glickstein combines his business expertise, acquired from companies ranging from startups to corporate entities, with his background in biology and environmental studies. His biology background and entrepreneurial experiences give him the ability to bridge the gap between science and the market, a crucial role in the biotechnology industry. His past experiences include leading roles in various agricultural and biotech companies, including hydroponic farming, insect rearing, and protein biotechnology. Mr. Glickstein will lead BSD’s business management, aiding in the day-to-day operations and organization of the core business activities.
Dr. Reed is a Registered Patent Agent and molecular biologist with nearly two decades of intellectual property management experience in industry and academia. She has successfully prosecuted a portfolio of patent applications in the US Patent and Trademark Office. Her expertise is deepest in the areas of biotechnology, medical treatments and medical devices. She has extensive hands-on experience with recombinant DNA & RNA techniques, design and analysis of transgenic mice, gene regulation, and clinical laboratory medicine, most recently at the University of Cincinnati where she earned her PhD. Dr. Reed co-founded Genomatix, the forerunner to Intrexon, in 1998 as Intellectual Property Manager and will serve in a similar capacity with BSD. Dr. Reed is also employed as a Patent Agent at the law firm of W&C IP, PC, located in Reston VA.